An interventional study of CREDOenAP intervention in Type 2 Diabetes Mellitus (T2DM), sponsored by Parc Sanitari Pere Virgili. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Parc Sanitari Pere Virgili · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 307th largest by planned enrollment of the 383 interventional ones that give a count, is one of 24 that started in 2026, is one of 77 with no phase, reaches primary completion later than 24 of the 54 other live ones, and was the 402nd registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Spain, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 49 · Phase 3 209 · Phase 4 51
First in 2000; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 484 across the 383 interventional studies, 842 across the 46 observational. Of the 346 that completed or were terminated, 197 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
304 of 429 have an industry lead sponsor. The 10 most frequent:
Parc Sanitari Pere Virgili is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
Parc Sanitari Pere Virgili has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 2 with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07269015Hospital Mutua de TerrassaCGM Accuracy in Pregnancy Study | 2026-12 |
| NCT06871059University of the Balearic IslandsEffectiveness, Implementation and Spillover Effects of a Culturally Adapted DPP in Spanish Primary Care Centers | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to determine whether an intensive lifestyle intervention can achieve remission of type 2 diabetes mellitus (T2DM) in adult patients treated in primary care. The main questions the study seeks to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The program consists of biweekly in-person and telephone visits, focused on implementing a personalized dietary plan with carbohydrate restriction, based on the American Diabetes Association recommendations; moderate and accessible physical activity; circadian rhythm regularization; and psychological counseling and support.
Behavioral: CREDOenAP intervention
They will receive the standard clinical treatment for diabetes
Intervention program with intensive lifestyle counseling, added to standard pharmacological treatment subsequently adjusted according to clinical needs and outcomes. The intervention will last 6 months and consists of biweekly in-person and telephone visits. Patients will follow a personalized dietary plan with carbohydrate restriction, based on the recommendations of the American Diabetes Association; engage in moderate and accessible physical activity; implement circadian rhythm regularization; and receive psychological counseling and support.
Presence of T2DM remission
Glycated hemoglobin (HbA1c): T2DM remission will be considered if HbA1c is \< 6.5% after 6 months of intervention and at least 3 months without antidiabetic medication. HbA1c will be determined by blood analysis after a minimum of 8 hours of fasting Fasting plasma glucose: T2DM remission will be considered if fasting venous plasma glucose is \< 126 mg/dL after 6 months of intervention and at least 3 months without antidiabetic medication. Fasting plasma glucose will be measured by venous blood analysis after a minimum of 8 hours of fasting
Time frame: After 6 months of intervention and 12 months after the intervention
Blood pressure
Blood pressure will be measured three times after the participant has been seated at rest for 10 minutes with uncrossed legs. The mean of the last two measurements will be used for statistical analysis. Systolic and diastolic blood pressure will be reported in mmHg using a brachial cuff sphygmomanometer.
Time frame: After 6 months of intervention and 12 months after the intervention.
Total cholesterol
Measured in mg/dL via blood analysis.
Time frame: After 6 months of intervention and 12 months after the intervention
HDL cholesterol
High-density lipoprotein (HDL) cholesterol measured in mg/dL via blood analysis.
Time frame: After 6 months of intervention and 12 months after the intervention
LDL cholesterol
Low-density lipoprotein (LDL) cholesterol measured in mg/dL via blood analysis.
Time frame: After 6 months of intervention and 12 months after the intervention
Apolipoprotein B100 (ApoB100)
A protein involved in cholesterol transport and relevant for evaluating elevated cholesterol causes, measured in mg/dL via blood analysis.
Time frame: After 6 months of intervention and 12 months after the intervention
Triglycerides
Measured in mg/dL via blood analysis
Time frame: After 6 months of intervention and 12 months after the intervention
Presence and size of atherosclerotic plaques in carotid arteries
Assessed via Doppler ultrasound of the supraaortic trunks. If plaques are present, the total plaque area will be measured in cm², and changes in plaque area will be tracked throughout the study.
Time frame: After 6 months of intervention and 12 months after the intervention
Weight
Measured in kilograms (kg)
Time frame: After 6 months of intervention and 12 months after the intervention
Body Mass Index (BMI)
Calculated from weight and height using the formula: BMI = weight (kg) / \[height (m)\]².
Time frame: After 6 months of intervention and 12 months after the intervention
Abdominal circumference
Measured at the midpoint between the lowest rib and the iliac crest during maximal inspiration and expiration, in centimeters (cm)
Time frame: After 6 months of intervention and 12 months after the intervention
Insulin resistance
Evaluated using the HOMA-IR index (Homeostasis Model Assessment of Insulin Resistance), which estimates insulin resistance and beta-cell function. Determined via blood analysis after a minimum 8-hour fast. Values above 2.5 may indicate T2D. Calculated as: \[fasting insulin (μU/mL) x glucemia basal (mmol/L)\] / 22.5 = \[fasting insulin (μU/mL) x (Glucemia basal (mg/dL) x 0,0555)\] / 22.5
Time frame: After 6 months of intervention and 12 months after the intervention
Pancreatic activity
Assessed using the HOMA-B index, which evaluates the function and activity of pancreatic beta cells. HOMA-B, together with HOMA-IR, helps in the diagnosis of T2D. Values between 167 and 175 are considered normal and not indicative of T2D. Values below this range suggest impaired beta-cell function, resulting in insufficient insulin production (insulinopenia).
Time frame: After 6 months of intervention and 12 months after the intervention
Fasting insulin
Measures the amount of insulin in a blood sample. Insulin is a hormone produced by the pancreas. Normal values range between 5-25 U/mL. It will be measured via blood analysis after a minimum 8-hour fast.
Time frame: After 6 months of intervention and 12 months after the intervention
Metabolic Syndrome Diagnosis
Metabolic Syndrome Diagnosis is established if at least three of the following five criteria are present: * Abdominal circumference: Men of European descent \> 94 cm; Women of European descent \> 80 cm. For other ethnicities, cut-off points are defined according to the International Diabetes Federation (IDF). (López De La Torre et al., 2010) * Fasting glucose: \> 100 mg/dL or receiving pharmacological treatment for hyperglycemia. * Triglycerides: \> 150 mg/dL or receiving lipid-lowering therapy. * HDL cholesterol: \< 40 mg/dL in men; \< 50 mg/dL in women, or receiving lipid-lowering therapy. * Blood pressure: Systolic \> 130 mmHg or Diastolic \> 85 mmHg, or receiving antihypertensive treatment.
Time frame: After 6 months of intervention and 12 months after the intervention
NAFLD Liver Fat Score
Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excessive fat accumulation in the liver. Its severity can vary according to the score: \< -1.455 low risk, -1.455 to 0.675 intermediate risk, \> 0.675 high risk (Angulo et al., 2007; Kotronen et al., 2009). The calculation is determined using the following formula: -2.89 + 1.18 × Metabolic Syndrome (Yes = 1 / No = 0) + 0.45 × T2DM (Yes = 2 / No = 0) + 0.15 × Fasting Insulin (mU/L) + 0.04 × Fasting Serum AST (U/L) - 0.94 × AST/ALT ratio
Time frame: After 6 months of intervention and 12 months after the intervention
NAFLD Fibrosis Score
The identification and quantification of fibrosis are clinically relevant since fibrosis is associated with an unfavorable clinical prognosis. An NFS \> 0.676 indicates the presence of advanced fibrosis (Angulo et al., 2007; Kotronen et al., 2009). The calculation is determined using the following formula: -1.675 + 0.037 × Age (years) + 0.094 × BMI (kg/m²) + 1.13 × IFG/diabetes (Yes = 1 / No = 0) + 0.99 × AST/ALT ratio - 0.013 × Platelets (×10⁹/L) - 0.66 × Albumin (g/dL)
Time frame: After 6 months of intervention and 12 months after the intervention
Physical activity
Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ)
Time frame: After 6 months of intervention and 12 months after the intervention
Nutritional and energy composition:
The 24-hour dietary recall questionnaire will be administered at each biweekly visit
Time frame: After 6 months of intervention and 12 months after the intervention
Smoking habits
Measured by a study-specific questionnaire
Time frame: After 6 months of intervention and 12 months after the intervention
Alcohol consumption
Alcohol intake will be quantified using a questionnaire combined with a standardized alcohol unit conversion calculator
Time frame: After 6 months of intervention and 12 months after the intervention
Circadian habits
Measured by a study-specific questionnaire
Time frame: After 6 months of intervention and 12 months after the intervention
Health status
SF-36: This is a generic scale that provides a health status profile and is applicable both to patients and to the general population
Time frame: After 6 months of intervention and 12 months after the intervention
Medication consumption
Defined Daily Dose (DDD) by active substance: DDDs of the active substances consumed will be classified according to ATC7. Each ATC classification has a defined daily dose based on international standards, which determine the recommended maximum daily amount for the approved indication of the active substance
Time frame: After 6 months of intervention and 12 months after the intervention
Number of hypoglycemia episodes
Episodes of hypoglycemia detected by patients through capillary blood glucose levels and/or recorded in eCAP during the intervention (plasma glucose \<60 mg/dl)
Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention
Number of symptomatic hyperglycemia episodes
Episodes of hyperglycemia recorded in eCAP during the intervention (plasma glucose \>350 mg/dl accompanied by compatible symptoms such as general malaise, nausea, asthenia, among others)
Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention
Total number of healthcare visits
Annual contacts with the healthcare system including Primary Care (physicians and nursing), Specialized Care, and Emergency Care
Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention
Number of diabetes-related emergency episodes
Emergency visits related to diabetes during the intervention period
Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention
Plan to share: No
Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 17 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Parc Sanitari Pere Virgili